Related Experiment Videos
ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease
Jessica Sarahi Alavez-Rubio1, Teresa Juarez-Cedillo2
1Universidad Nacional Autonoma de México, Mexico City, Mexico.
Background:
Alzheimer´s disease (AD) is a chronic and progressive disease which impacts caregivers, families and societies physically, psychologically and economically. Currently available drugs can only improve cognitive symptoms, have no impact on progression and are not curative, so identifying and studying new drug targets is important. There are evidences which indicate disturbances in cholesterol homeostasis can be related with AD pathology, especially the compartmentation of intracellular cholesterol and cytoplasmic cholesterol esters formed by acyl-CoA: cholesterol acyltransferase 1 (ACAT1) can be implicated in the regulation of amyloid-beta (Aβ) peptide, involved in AD. Blocking ACAT1 activity, beneficial effects are obtained, so it has been suggested that ACAT1 can be a potential new therapeutic target. The present review discusses the role of cholesterol homeostasis in AD pathology, especially with ACAT inhibitors, and how they have been raised as a therapeutic approach. In addition, the genetic relationship of ACAT and AD is discussed.
Conclusion:
Although there are several lines of evidence from cell-based and animal studies that suggest that ACAT inhibition is an effective way of reducing cerebral Aβ, there is still an information gap in terms of mechanisms and concerns to cover before passing to the next level. Additionally, an area of interest that may be useful in understanding AD to subsequently propose new therapeutic approaches is pharmacogenetics; however, there is still a lot of missing information in this area.
Insights
Targeting acyl-CoA: cholesterol acyltransferase 1 (ACAT1) may offer a new therapeutic strategy for Alzheimer's disease (AD). Inhibiting ACAT1 shows promise in reducing amyloid-beta, a key factor in AD pathology.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) poses significant physical, psychological, and economic burdens.
- Current AD treatments only manage cognitive symptoms and do not halt disease progression.
- Disturbances in cholesterol homeostasis, particularly involving acyl-CoA: cholesterol acyltransferase 1 (ACAT1), are linked to AD pathology and amyloid-beta (Aβ) regulation.
Purpose of the Study:
- To review the role of cholesterol homeostasis in AD pathology.
- To discuss acyl-CoA: cholesterol acyltransferase 1 (ACAT1) inhibitors as a potential therapeutic approach for AD.
- To explore the genetic relationship between ACAT and AD.
Main Methods:
- Review of existing literature on cholesterol homeostasis, ACAT1, and Alzheimer's disease.
- Analysis of evidence linking ACAT1 activity to amyloid-beta (Aβ) peptide regulation.
- Discussion of ACAT inhibitors as a therapeutic strategy.
Main Results:
- Evidence suggests that blocking ACAT1 activity yields beneficial effects in AD models.
- ACAT1 is implicated in the regulation of amyloid-beta (Aβ) peptide, a key component of AD pathology.
- ACAT1 inhibitors are emerging as a potential therapeutic target for Alzheimer's disease.
Conclusions:
- ACAT1 inhibition shows promise in reducing cerebral Aβ, supported by cell-based and animal studies.
- Further research is needed to elucidate mechanisms and address concerns before clinical application.
- Pharmacogenetics offers a potential avenue for understanding AD and developing novel therapeutic approaches, though significant information gaps remain.